Dyslipidemia Prevalence, Perception, Treatment, and Awareness in the Tunisian Population

Dyslipidemia Prevalence, Perception, Treatment, and Awareness in the Tunisian Population : The ATERA Survey

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03799185

Acronym

ATERASurvey

Enrollment

13610

Registered

2019-01-10

Start date

2016-01-04

Completion date

2019-08-31

Last updated

2020-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, Dyslipidemias, Households, Survey, Family Life

Keywords

Coronary Heart Disease, Hypercholesterolemia, Triglycerides High, LDL Hyperlipoproteinemia, HDL Low, Diabetes, Cardiovascular Diseases, Hypertension, Risk Factor, Cardiovascular, Diet Habit, Smoking

Brief summary

ATERA Survey is a national cross sectional observational study, aiming to determine the prevalence of dyslipidemia and other conventional risk factors for CHD (Coronary Heart Disease), the relationship between environmental and lifestyle factors with dyslipidemia, the perception and the knowledge of cardiovascular risk factors by the population, and above all, to strengthen the national strategy for primary and secondary prevention against coronary heart disease.

Detailed description

ATERA Survey is carried on in a random sampling including 10 000 men and women from the seven regions of Tunisia (Great Tunis, North East, North West, central East, Central West, South East and South West. The screening is being assessed using surveys covering socioeconomic, nutritional and anthropometric measures in addition to biological assessments. The target population is being recruited by random sampling drown by the National Institute of Statistics (Tunisia). The estimated number of participants at the end of recruitment amount to 10 000. The frame sampling uses a two stage cluster sampling (district and household). Interview with each eligible participant will be conducted mainly during assessment visit and after consenting the subject, it will be notified all the demographic, behavioral history, family history, cardiovascular risk factors and medical history. During the assessment visit, Physical examination/anthropometry data and Diet survey will be filled up by the investigator. Data capture will be performed by the DACIMA Clinical Suite according to FDA 21 CFR part 11 requirements (Food and Drug Administration 21 Code of Federal Regulations part 11), the HIPAA specifications (Health Insurance Portability and Accountability Act), and the ICH standards (International Conference on Harmonisation)

Interventions

None listed

Study design

Observational model

FAMILY_BASED

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

25 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* All subjects

Exclusion criteria

* Prescribed treatment for cancer * Organ transplantation * Known auto-immune disease * Severe liver disease * Chronic renal failure * Pregnant women

Design outcomes

Primary

Measure	Time frame	Description
Prevalence of dyslipidemia	At inclusion	Frequency of subjects with hypercholesterolemia and/or hypertriglyceridaemia

Secondary

Measure	Time frame	Description
Prevalence of cardiovascular associated risk factors	At inclusion	Frequency of subjects with cardiovascular risk factors (diabetes, hypertension, obesity, gender, smoking)

Other

Measure	Time frame	Description
Dietary assessment	Up to 1 month	Frequency of diet daily intake (fat, sugar, proteins, fiber)

Countries

Tunisia

Outcome results